A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study

被引：0
|
作者：
Yasushi Sato
Masahiro Hirakawa
Hiroyuki Ohnuma
Minoru Takahashi
Tetsuro Okamoto
Koichi Okamoto
Hiroshi Miyamoto
Naoki Muguruma
Tomohisa Furuhata
Ichiro Takemasa
Junji Kato
Tetsuji Takayama
机构：
[1] Tokushima University Graduate School of Biomedical Sciences,Department of Community Medicine for Gastroenterology and Oncology
[2] Sapporo Medical University School of Medicine,Department of Medical Oncology
[3] Sapporo Kyoritsu Gorinbashi Hospital,Division of Gastroenterology
[4] Kiyota Hospital,Division of Gastroenterology
[5] Tokushima University Graduate School of Biomedical Sciences,Department of Gastroenterology and Oncology
[6] St. Marianna Medical University Toyoko Hospital,Department of Gastroenterological Surgery
[7] Sapporo Medical University School of Medicine,Department of Surgery, Surgical Oncology and Science
来源：
Cancer Chemotherapy and Pharmacology | 2017年 / 80卷
关键词：
Colorectal cancer; Capecitabine; Irinotecan; Oxaliplatin; Cetuximab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1133 / 1139
页数：6
相关论文
共 50 条
  • [1] A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study
    Sato, Yasushi
    Hirakawa, Masahiro
    Ohnuma, Hiroyuki
    Takahashi, Minoru
    Okamoto, Tetsuro
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Furuhata, Tomohisa
    Takemasa, Ichiro
    Kato, Junji
    Takayama, Tetsuji
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1133 - 1139
  • [2] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
    Sato, Yasushi
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Minoru
    Osuga, Takahiro
    Okagawa, Yutaka
    Murase, Kazuyuki
    Takada, Kohichi
    Kawano, Yutaka
    Iyama, Satoshi
    Hayashi, Tsuyoshi
    Sato, Tsutomu
    Miyanishi, Koji
    Takimoto, Rishu
    Kobune, Masayoshi
    Okita, Kenji
    Mizuguchi, Toru
    Furuhata, Tomohisa
    Hirata, Koichi
    Kato, Junji
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 587 - 594
  • [3] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
    Yasushi Sato
    Hiroyuki Ohnuma
    Masahiro Hirakawa
    Minoru Takahashi
    Takahiro Osuga
    Yutaka Okagawa
    Kazuyuki Murase
    Kohichi Takada
    Yutaka Kawano
    Satoshi Iyama
    Tsuyoshi Hayashi
    Tsutomu Sato
    Koji Miyanishi
    Rishu Takimoto
    Masayoshi Kobune
    Kenji Okita
    Toru Mizuguchi
    Tomohisa Furuhata
    Koichi Hirata
    Junji Kato
    [J]. Cancer Chemotherapy and Pharmacology, 2015, 75 : 587 - 594
  • [4] A triplet combination with oxaliplatin/capecitabine/irinotecan (XELOXIRI) plus cetuximab (Cmab) as a first-line therapy in wild-type KRAS, metastatic colorectal cancer: a dose escalating study
    Sato, Y.
    Ohnuma, H.
    Hirakawa, M.
    Kikuch, S.
    Takahashi, M.
    Okamoto, T.
    Tsuji, Y.
    Okita, K.
    Furuhata, T.
    Takemasa, I.
    Kato, J.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [5] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab (bev) as a first-line therapy for patients with metastatic colorectal cancer
    Sato, Yasushi
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Minoru
    Osuga, Takahiro
    Takada, Kohichi
    Hayashi, Tsuyoshi
    Sato, Tsutomu
    Miyanishi, Koji
    Takimoto, Rishu
    Kobune, Masayoshi
    Okita, Kenji
    Furuhata, Tomohisa
    Hirata, Koichi
    Kato, Junji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [6] Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer
    Masi, Gianluca
    Vasile, Enrico
    Loupakis, Fotios
    Bursi, Simona
    Ricci, Sergio
    Petrini, Iacopo
    Fontana, Andrea
    Allegrini, Giacomo
    Falcone, Alfredo
    [J]. CLINICAL COLORECTAL CANCER, 2008, 7 (01) : 7 - 14
  • [7] Results of the use of oxaliplatin and capecitabine plus cetuximab as first-line therapy in the treatment of patients with metastatic colorectal cancer:: First analyses
    Barroso, S.
    Sanches, E.
    Marques, Ferreira J.
    Passos, M.
    Sa, A.
    Nabico, R.
    Sottomayor, C.
    Espirito, Santo J.
    San-bento, R.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 74 - 75
  • [8] RESULTS OF THE USE OF OXALIPLATIN AND CAPECITABINE PLUS CETUXIMAB AS FIRST-LINE THERAPY IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER: FIRST ANALYSES
    Barroso, S.
    Sanches, E.
    Ferreira, J. M.
    Passos, M.
    Sa, A.
    Nabico, R.
    Sotto-Mayor, C.
    Santo, J. Espirito
    San-Bento, R.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 148 - 148
  • [9] XELOX (capecitabine plus oxaliplatin):: Active first-line therapy for patients with metastatic colorectal cancer
    Cassidy, J
    Tabernero, J
    Twelves, C
    Brunet, R
    Butts, C
    Conroy, T
    Debraud, F
    Figer, A
    Grossmann, J
    Sawada, N
    Schöffski, P
    Sobrero, A
    Van Cutsem, E
    Diaz-Rubio, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) : 2084 - 2091
  • [10] Results of a Phase II Trial of Cetuximab plus Capecitabine/Irinotecan as First-Line Therapy for Patients with Advanced and/or Metastatic Colorectal Cancer
    Cartwright, Thomas
    Kuefler, Paul
    Cohn, Allen
    Hyman, William
    Berger, Maury
    Richards, Donald
    Vukelja, Svetislava
    Nugent, John E.
    Ruxer, Robert L., Jr.
    Boehm, Kristi A.
    Asmar, Lina
    [J]. CLINICAL COLORECTAL CANCER, 2008, 7 (06) : 390 - 397
12345